Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer SWOG S0536

Journal of Thoracic Oncology

Volumn 8, Issue 12, 2013, Pages 1519-1528

  Kim, Edward S ^a   Moon, James ^b   Herbst, Roy S ^c   Redman, Mary W ^b   Dakhil, Shaker R ^d   Velasco, Mario R ^e   Hirsch, Fred R ^f   Mack, Philip C ^g   Kelly, Karen ^g   Heymach, John V ^h   Gandara, David R ^g  

^a LEVINE CANCER INSTITUTE   (United States)

^b SWOG STATISTICAL CENTER   (United States)

^c YALE CANCER CENTER   (United States)

^d Cancer Center of Kansas   (United States)

^e Cancer Care Specialists of Central Illinois   (United States)

^f UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bevacizumab; Carboplatin; Cetuximab; Frontline; Non small cell lung cancer; Paclitaxel

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; PACLITAXEL; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COLON PERFORATION; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EMBOLISM; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; INFECTION; LOADING DRUG DOSE; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SENSORY NEUROPATHY; SKIN MANIFESTATION; THROMBOSIS; TREATMENT RESPONSE; ADENOCARCINOMA; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; FEASIBILITY STUDY; FOLLOW UP; LUNG NEOPLASMS; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CETUXIMAB; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; SURVIVAL RATE;

EID: 84892364384     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000009     Document Type: Article

References (19)

1. Schiller JH, Harrington D, Belani C P, et al; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
2. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004;22:777-784.
3. Herbst RS, Prager D, Hermann R, et al; TRIBUTE Investigator Group. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-5899.
4. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
5. Pirker R, Pereira JR, Szczesna A, et al; FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373:1525-1531.
6. Lynch TJ, Patel T, Dreisbach L, et al: A Randomized multicenter phase III study of cetuximab (Erbitux) in combination with taxane/carboplatin alone as first-line treatment for patients with advanced/meta-static non-small cell lung cancer (NSCLC): B3-02. J Thorac Oncol 2007;2(Suppl):S340-S341.
7. Herbst RS, Kelly K, Chansky K, et al. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. J Clin Oncol 2010;28:4747-4754.
8. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563-572.
9. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009;27:672-680.
10. Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005;23:7889-7896.
11. Hainsworth J, Lin M, O'Connor P, et al. A phase III, multicenter, placebo-controlled, double-blind, randomized, clinical trial to evaluate the efficacy of bevacizumab (Avastin®) in combination with erlotinib (Tarceva®) compared with erlotinib alone for treatment of advanced non-small cell lung cancer (NSCLC) after failure of standard first line chemotherapy (BETA). Lancet 2011;377(9780):1846-1854.
12. Miller VA, O'Connor P, Soh C, et al. A randomized, double-blind placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or meta-static non-small cell lung cancer (NSCLC). J Clin Oncol 2009;27(18S): LBA8002
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. JASA 1958;53:457-481.
15. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics, 38:29-41, 1982.
16. Cox DR. Regression models and life tables. J R Stat Soc Ser B, 34:187-202, 1972.
17. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-1234.
18. De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010;304:1812-1820.
19. Blanke CD, Goldberg RM, Grothey A, et al.; NCI GI Steering Committee Colon Cancer Task Force. KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice. Oncologist 2011;16:1061-1068.